|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 24, 2017 ) Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
Publisher's analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-benign-prostatic-hyperplasia-bph-drugs-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Astellas Pharma
- Eli Lilly
- GlaxoSmithKline
- Sanofi
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001778475/sample .
Other prominent vendors
- ADC Therapeutics
- Advaxis
- Agennix
- ANI Pharmaceuticals
- Bayer HealthCare
- BHR Pharma
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Dendreon (Valeant Pharmaceuticals)
- Eisai
- Endo Pharmaceuticals
- Ferring
- Foresee Pharmaceuticals
- Io Therapeutics
- LIDDS
- Madrigal Pharmaceuticals
- Merck
- Novartis
- Nymox Pharmaceutical
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals
- Teva Pharmaceutical Industries
- Urologix
Market driver
- Growing geriatric male population.
- For a full, detailed list, view our report
Market challenge
- Availability of minimally invasive surgery as a drug replacement.
- For a full, detailed list, view our report
Market trend
- Advancements in early-stage diagnosis through new diagnostic methods.
- For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001778475/buying .
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
